Kinase Inhibitor

Organic Cation Transporter 2 Inhibitors

Multidrug and Toxin Extrusion Transporter 1 Inhibitors

Cyclin-dependent Kinase 4 Inhibitors

Cyclin-dependent Kinase 6 Inhibitors

Multidrug and Toxin Extrusion Transporter 2 K Inhibitors

<section class="Section" data-sectioncode="34089-3"><a name="s42"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">COSELA for injection contains trilaciclib dihydrochloride, a kinase inhibitor.</p><p>The chemical name for trilaciclib is 2'-{[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino}-7',8'-dihydro-6'<span class="Italics">H</span>-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-<span class="Italics">d</span>]pyrimidin]-6'-one.</p><p>Trilaciclib dihydrochloride is a water-soluble yellow solid, with molecular formula of C<span class="Sub">24</span>H<span class="Sub">30</span>N<span class="Sub">8</span>O•2HCl, a molecular weight of 519.48 g/mol (Free base: 446.56 g/mol), and the following chemical structure:</p><div class="Figure"><a name="f01"></a><img alt="Chemical Structure
" src="cos07-0002-01.jpg"/></div><p>COSELA (trilaciclib) for injection is a sterile, preservative-free, yellow lyophilized cake in a single-dose vial for intravenous infusion after reconstitution and dilution.</p><p>Each single-dose vial contains the equivalent of 300 mg of trilaciclib (provided as 349 mg of trilaciclib dihydrochloride) and the following inactive ingredients: citric acid monohydrate (75.6 mg) and mannitol (300 mg); hydrochloric acid and sodium hydroxide to adjust pH.</p></section>

COSELA

trilaciclib

trilaciclib 300 MG Injection

Cosela

trilaciclib 300 MG Injection [Cosela]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Pharmacy List 

Submit MSL Request 

Billing & Coding Guide 

Prior Authorization Checklist 

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity 

G1 to One Enrollment Form For Cosela 

Other HCP Resources 

Enroll in Patient Savings Program 

G1 to One Patient Support Program Brochure

About Cosela 

Receiving Cosela 

Side Effects

FAQs: Myeloprotection in ES‑SCLC Patients

Instructions For Use: Myeloprotection in ES‑SCLC Patients

Patient Brochure 

G1 to One Patient Support Program 